Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Corporate Life Sciences Lawyer (3-5 years exp)||
Ropes & Gray LLP
|Boston, MA; San Francisco, CA; Silicon Valley, CA, MA|
|Director of Accreditation||
Meridian Health Plan
|Health Services Researcher||
|Chief Executive Officer||
Center for Improving Value in Healthcare
|Senior director risk adjustor and coding doc||